BioMarin Pharmaceutical Inc. (BMRN)

About BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.

Super investor ownership

15 of the funds we track reported a position in their latest SEC 13F filing. Largest first:

• Dodge & Cox, DODGE & COX$849.43M · 0.4% of book
• Andreas Halvorsen, VIKING GLOBAL INVESTORS LP$435.82M · 1.2% of book
• Cliff Asness, AQR CAPITAL MANAGEMENT LLC$322.54M · 0.1% of book
• Capital Research Global, Capital Research Global Investors$200.52M · 0.0% of book
• Israel Englander, MILLENNIUM MANAGEMENT LLC$118.55M · 0.0% of book

A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.

Politician trades in BMRN

We hold 8 disclosed trades in BMRN by members of Congress and executive-branch officials. The latest 5:

• Daniel Goldman · HouseSell · $1,001 - $15,000 · traded 6 Mar 2023 · disclosed 17 Apr 2023
• Gilbert Cisneros · HouseBuy · $15,001 - $50,000 · traded 30 Dec 2020 · disclosed 11 Jan 2021
• Alan S. Lowenthal · HouseSell · $1,001 - $15,000 · traded 15 Aug 2019 · disclosed 1 Sept 2019
• Alan S. Lowenthal · HouseSell · $1,001 - $15,000 · traded 14 Aug 2019 · disclosed 1 Sept 2019
• Alan S. Lowenthal · HouseBuy · $1,001 - $15,000 · traded 27 Apr 2018 · disclosed 3 May 2018

A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.

Common questions